Strona główna・Stock List・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Closed

SectorHealthcare

110.45 0.38

Buy Sell

Overview

Share price change

24h

Current

Min

108.05

Max

111.61

Key metrics
By Trading Economics
Income	18M -69M
Sales	32M 34M
EPS	-0.71
Profit margin	-201.467
Employees	253
EBITDA	18M -67M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+17.84% upside

Dividends
By Acuity
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	2.1B 9.1B
Previous open	110.07
Previous close	110.45

News Sentiment

By Acuity

50%

163 / 340 Ranking in Healthcare

Kymera Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lip 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 lip 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 lip 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

17.84% upside

12 Months Forecast

Average 130.07 USD 17.84%

High 155 USD

Low 115 USD

Based on 16 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Kymera Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

163 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.